19 annual accounts with figures on one time axis, 23 filings since 2003
peak of €162,153 in 2022
€1,422▲ €2,635
lowest -€510,256 in 2023
€716▲ €1,985
peak of €419,160 in 2022
-€91,649▲ €716
€386,901▼ 0.8%
peak of 0.7 FTE in 2007
-not published
Board1 name since 2025
1 directorName after signing inVisible after signing in
Documentsfilings and deeds
03-12-202559 days before the deadline
2025micro format
Gross margin from -€1,213 to €1,422Profit of €716, after a lossMerger proposal: to be absorbed by DUVIPHAR30-12Hidden nameVisible after signing in resigns as director20-06
Key points
from the 2025 annual accounts, the last ones filed
Merger: absorbed by DUVIPHARDUVIPHAR holds all the shares · General meeting of 25-02-2026 · Gazette deed
Merger proposal: to be absorbed by DUVIPHAR
Gazette deed
Name after signing inVisible after signing in resigns as directorName hiddenVisible after signing in appointed as director · General meeting of 26-05-2025 · Gazette deed
1 manager resigning, 1 director reappointedHidden nameVisible after signing in resigns as manager · Name after signing inVisible after signing in reappointed as director · Name hiddenVisible after signing in acts as permanent representative · General meeting of 29-05-2020 · Gazette deed
The turnover in financial year 2025 is about €11,000. This figure is estimated from the gross margin of €1,422 and 7,102 comparable companies of the same size. It probably lies between €4,800 and €25,000. It is a rough estimate.Financials
Is TRICHERES PHARMA profitable?
In financial year 2025, TRICHERES PHARMA made a profit of €716.
Where can I find the annual accounts of TRICHERES PHARMA?
TRICHERES PHARMA filed 23 annual accounts with the National Bank of Belgium, the latest for financial year 2025.